GLP-1 receptor agonists in pediatric obesity and diabetes: a systematic review of efficacy, metabolic effects, and safety
Authors' conclusion
GLP-1 RAs are effective adjuncts for pediatric obesity and T2DM
Study context
- Population
- Children and adolescents aged 6 to <18 years with obesity or T2D; PubMed-indexed studies 2000–20257 RCTs and 6 meta-analyses
- Participants
- 901 children
- Comparison
- GLP-1 RAs vs placebo
- Outcome
- Efficacy of GLP-1 RAs
Pooled result
As reported in the abstract
- Semaglutide 2.4 mg/week produced the greatest BMI reduction in adolescents with obesity, followed by liraglutide 3.0 mg/day
- Liraglutide 3.0 mg/day also improved BMI SDS in adolescents and younger children
- In youth-onset T2D, liraglutide 1.8 mg/day and dulaglutide significantly improved HbA1c vs placebo
Further pooled results
Metabolic effects
- Weight-reducing agents improved insulin resistance and modestly reduced TG; LDL-C changes were minimal
Safety
- Gastrointestinal adverse events, mainly nausea and vomiting, were most frequent, generally transient and dose dependent
- No significant adverse effects on linear growth or pubertal progression were reported
Original publication
GLP-1 receptor agonists in pediatric obesity and diabetes: a systematic review of efficacy, metabolic effects, and safety. Diabetes Res Clin Pract. Published 28 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →